selective pan-FLT3-ITD kinase inhibitor (University of Arizona)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameselective pan-FLT3-ITD kinase inhibitor (University of Arizona)
Drug Alias Nameselective pan-fms-like tyrosine kinase 3-internal tandem duplication kinase inhibitor (University of)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Arizona
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Arizona
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A